2-甲基-4-硝基吲哚 | 3484-10-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-甲基-4-硝基吲哚
• 中文别名: 2-甲基-4-硝基-1H-吲哚
• 英文名称: 2-methyl-4-nitroindole
• 英文别名: 2-methyl-4-nitro-1H-indole
• CAS: 3484-10-4
• 化学式: C₉H₈N₂O₂
• mdl: MFCD09028445
• 分子量: 176.175
• InChiKey: HCISKOUSZIJNET-UHFFFAOYSA-N

物化性质

• 熔点：
  192-194 °C
• 沸点：
  365.6±22.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  2-甲基-4-硝基吲哚 在 铁粉 、 氯化铵 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 为溶剂， 反应 12.0h， 生成 N-(2-methyl-1H-indol-4-yl)acetamide
  参考文献：
  名称：

  Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer

  摘要：

  Valosine containing protein (VCP/p97) is a member of the AAA ATPase family involved in several essential cellular functions and plays an important role in the ubiquitin-mediated degradation of misfolded proteins. P97 has a significant role in maintaining the cellular protein homeostasis for tumor cell growth and survival and has been found overexpressed in many tumor types. No new molecule entities based on p97 target were approved in clinic. Herein, a series of novel pyrimidine structures as p97 inhibitors were designed and synthesized. After enzymatic evaluations, structure-activity relationships (SAR) were discussed in detailed. Among the screened compounds, derivative 35 showed excellent enzymatic inhibitory activity (IC50, 36 nM). The cellular inhibition results showed that compound 35 had good antiproliferative activity against the non-small cell lung cancer A549 cells (IC50, 1.61 mu M). Liver microsome stability showed that the half-life of compound 35 in human liver microsome was 42.3 min, which was more stable than the control CB-5083 (25.8 min). The in vivo pharmacokinetic results showed that the elimination phase half-lives of compound 35 were 4.57 h for ig and 3.64 h for iv, respectively and the oral bioavailability was only 4.5%. These results indicated that compound 35 could be effective for intravenous treatment of non-small cell lung cancer.

  DOI：

  10.1016/j.bmc.2018.12.036
• 作为产物：
  描述：

  ethyl N-(2-methyl-3-nitrophenyl)-acetimidate 在 potassium ethoxide 、 草酸二乙酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 以27%的产率得到2-甲基-4-硝基吲哚
  参考文献：
  名称：

  通过2-烷基硝基苯胺衍生物的闭环合成吲哚

  摘要：

  由草酸二烷基酯促进的碱诱导的环化反应，由2-烷基-3-或5-硝基苯胺的亚氨酸酯，am和仲-苯胺衍生物制备了多种硝基吲哚。结果表明，在一个简单的操作中，基本上相同的方法也可用于合成相应的硝基吲哚-3-乙醛酸酯。讨论了合成潜力，并提出了一种机理。

  DOI：

  10.1016/s0040-4020(01)87932-1

文献信息

• NOVEL 6-5 BICYCIC HETEROCYCLIC DERIVATIVE AND MEDICAL USE THEREOF
  申请人：Sanwa Kagaku Kenkyusho Co., Ltd

  公开号：EP2036887A1

  公开（公告）日：2009-03-18

  An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is -CH2- or -CO-; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen atom or an alkyl group, etc.; R4 is a hydrogen atom or an alkyl group; R5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R6 is a hydrogen atom or an alkyl group; R7 is a hydrogen atom, etc.; R8 is a hydrogen atom, or an alkyl group, etc.; and E is -NHCO-G-COR12, etc. (wherein G is a single bond or an alkylene group, and R12 is a hydroxy group or an alkoxy group)].

  本发明的目的是提供一种药物，作为甲状腺激素受体配体，其在药物疗效和安全性上足够，并且具有作为药物的优秀作用。本发明提供了一种由以下通式（I）表示的化合物或其药用可接受的盐：[其中[化学公式2]是单键或双键；A是-CH2-或-CO-；X、Y和Z各自独立为氮原子或碳原子；R1是氢原子或芳烷基团；R2是烷基团或芳烷基团等；R3是氢原子或烷基团等；R4是氢原子或烷基团；R5是氢原子、烷基团或卤素低烷基团等；R6是氢原子或烷基团；R7是氢原子等；R8是氢原子或烷基团等；E是-NHCO-G-COR12等（其中G是单键或亚烷基团，R12是羟基或烷氧基）]。
• Discovery of Irreversible p97 Inhibitors
  作者：Rui Ding、Ting Zhang、Daniel J. Wilson、Jiashu Xie、Jessica Williams、Yue Xu、Yihong Ye、Liqiang Chen

  DOI：10.1021/acs.jmedchem.9b00144

  日期：2019.3.14

  Inhibitors of human p97 (also known as valosin-containing protein) have been actively pursued because of their potential therapeutic applications in cancer and other diseases. However, covalent and irreversible p97 inhibitors have not been well explored. Herein, we report our design, synthesis, and biological evaluation of covalent and irreversible inhibitors of p97. Among an amide and a reverse amide

  由于人类p97的抑制剂在癌症和其他疾病中的潜在治疗应用，因此人们一直在积极寻求抑制剂。然而，共价和不可逆的p97抑制剂尚未得到很好的研究。本文中，我们报告了p97的共价和不可逆抑制剂的设计，合成和生物学评估。在我们合成的一个酰胺和一个反向酰胺系列中，我们已经鉴定出一种p97抑制剂，其功能不可逆性已在体外和细胞中建立。同样重要的是，质谱分析揭示了该化合物标记的三个潜在的半胱氨酸残基，并且诱变和计算机建模表明，Cys522是主要位点，经修饰可能会损害p97的功能。在一起
• Novel N-acylated heterocycles
  申请人：Recordati S.A.

  公开号：US20030162777A1

  公开（公告）日：2003-08-28

  Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptors.

  描述了包含一种肌氨酸受体拮抗剂和一种对5-HT 1A 受体具有亲和力的N-酰化杂环衍生物的组合物，以及它们的对映体、二对映体、N-氧化物、多型体、溶剂合物和药用可接受盐。肌氨酸受体拮抗剂和N-酰化杂环，或其对映体、二对映体、N-氧化物、多型体、溶剂合物或药用可接受盐的组合，在治疗患有下尿路神经肌肉功能障碍和与5-HT 1A 受体相关疾病的患者中是有用的。
• Synthesis of 4- and 6-substituted nitroindoles
  作者：Nikolai Moskalev、Michał Barbasiewicz、Mieczysław Mąkosza

  DOI：10.1016/j.tet.2003.11.011

  日期：2004.1

  Enolizable ketones react with m-nitroaniline in the presence of strong base such as t-BuOK to give 4- and 6-substituted nitroindoles. The reaction proceeds via oxidative nucleophilic substitution of hydrogen in m-nitroaniline with enolate anions in positions ortho to the amino group giving anionic σH adducts that are additionally stabilized by intramolecular interaction between the amino and the carbonyl

  烯醇化的酮与反应米硝基苯胺在强碱的存在下，例如吨-BuOK，得到4-和6-取代的硝基吲哚。通过氢的氧化亲核取代反应的进行在米硝基苯胺与位置烯醇化物阴离子的邻位的氨基给予阴离子σ ħ被附加地通过氨基和羰基之间的分子内相互作用稳定的加合物。所述σ的自发氧化ħ加合物，随后所产生的拜耳型缩合邻-aminonitrobenzyl酮，得到4-和6-取代的硝基吲哚。讨论了该反应的范围及其基本机理。
• [EN] SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION<br/>[FR] INHIBITEURS DIRECTS À PETITES MOLÉCULES D'INTERACTION PROTÉINE-PROTÉINE DE KEAP1-NRF2
  申请人：UNIV RUTGERS

  公开号：WO2020150446A1

  公开（公告）日：2020-07-23

  This patent document diclsoes novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.

  这项专利文件披露了一种新颖的化合物和方法，通过使用这些新颖的化合物来预防或治疗与Keapl-Nrf2相互作用活性相关的疾病或状况。作为Keapl-Nrf2相互作用的直接抑制剂，本文披露的化合物比现有的间接抑制剂更具特异性，且不受各种不良影响，是潜在的化学预防和治疗剂的候选人，用于治疗涉及氧化应激和/或炎症的各种疾病或状况，包括但不限于癌症、糖尿病、阿尔茨海默病、帕金森病和溃疡性结肠炎等。